[Skip to Content]
Outline
Claim CME
PDF
HIV

Cancer in Transgender and Gender-Diverse PersonsA Review

To identify the key insights or developments described in this article
1 Credit CME
JAMA Oncology
Published Online: February 9, 2023
Review
Alberto Giovanni Leone, MD1;
Dario Trapani, MD2,3;
Matthew B. Schabath, PhD4;
Joshua D. Safer, MD5,6;
N. F. N. Scout, PhD7;
Matteo Lambertini, MD8,9;
Rossana Berardi, MD10;
Silvia Marsoni, MD11;
Francesco Perrone, MD12;
Saverio Cinieri, MD13;
Rosalba Miceli, PhD1;
Federica Morano, MD1;
Filippo Pietrantonio, MD1
Author Affiliations
  • 1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 2European Institute of Oncology, IRCCS, Milan, Italy
  • 3Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
  • 4H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
  • 5Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York, New York
  • 6Mount Sinai Center for Transgender Medicine and Surgery, New York, New York
  • 7National LGBT Cancer Network, Providence, Rhode Island
  • 8Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy
  • 9Department of Medical Oncology, Unità Operativa Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy
  • 10Oncology Clinic, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy
  • 11IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
  • 12Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
  • 13Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Italy
Read article on JAMA Network

MOC/CME Information

editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Read Article Claim CME
Abstract

Importance  Transgender and gender-diverse individuals face unique challenges, including barriers to health care access and inequities in treatment, that may influence cancer risk and outcomes.

Observations  In this narrative review, a scoping review was conducted focusing on primary and secondary prevention and epidemiology of cancer, barriers to health care services, and health care practitioners’ knowledge about specific issues pertaining to transgender and gender-diverse individuals. PubMed, the Cochrane Library, and Embase, were reviewed for citations from their inception to December 31, 2021. This review revealed that transgender and gender-diverse people had a high prevalence of tobacco consumption and alcohol use and high rates of infection with human papillomavirus (HPV) and HIV. Transgender and gender-diverse individuals were less likely to adhere to cancer screening programs and had a higher incidence of HIV- and HPV-associated cancers. Social and economic determinants seemed to drive these disparities in risk factors and outcomes. A lack of knowledge about gender minorities’ health needs among health care practitioners was evidenced, and it represented a major hurdle to cancer prevention, care, and survivorship for transgender and gender-diverse individuals. Discrimination, discomfort caused by gender-labeled oncological services, stigma, and lack of cultural sensitivity of health care practitioners were other barriers met by transgender and gender-diverse persons in the oncology setting.

Conclusions and Relevance  The findings suggest that transgender and gender-diverse peoples’ needs in the cancer care continuum are not optimally addressed. Effective solutions are needed to offer the best care to every patient in a person-centric and gender diversity–sensitive environment.

Sign in to take quiz and track your certificates

Buy This Activity
Our websites may be periodically unavailable between 12:00am CT March 25, 2023 and 4:00pm CT March 26, 2023 for regularly scheduled maintenance.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

See More About

Cancer Screening, Prevention, Control HIV Infectious Diseases Oncology Substance Use and Addiction Medicine Cancer Epidemiology Alcohol LGBTQIA Medicine
Article Information

Accepted for Publication: November 1, 2022.

Published Online: February 9, 2023. doi:10.1001/jamaoncol.2022.7173

Corresponding Author: Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy (filippo.pietrantonio@istitutotumori.mi.it).

Author Contributions: Drs Leone and Pietrantonio had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Leone, Trapani, Safer, Marsoni, Perrone, Cinieri, Pietrantonio.

Acquisition, analysis, or interpretation of data: Leone, Schabath, Scout, Lambertini, Berardi, Cinieri, Miceli, Morano, Pietrantonio.

Drafting of the manuscript: Leone, Trapani, Schabath, Marsoni, Cinieri, Miceli, Pietrantonio.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: Trapani, Lambertini, Morano.

Supervision: Leone, Trapani, Safer, Berardi, Marsoni, Perrone, Cinieri, Miceli, Morano, Pietrantonio.

Conflict of Interest Disclosures: Dr Schabath reported receiving personal fees from Bristol Myers Squibb outside the submitted work. Dr Lambertini reported having an advisory role for and receiving speaker honoraria from Roche, Novartis, Eli Lilly & Company, and Pfizer; having an advisory role for AstraZeneca, MSD, Exact Sciences, and Seagen; receiving speaker honoraria from Takeda, Sandoz, Ipsen, Knight, Libbs, and Daiichi Sankyo; and having an advisory role for and receiving travel support and a research grant (to the institution) from Gilead outside the submitted work. Dr Berardi reported receiving personal fees from Amgen, MSD, Bristol Myers Squibb, Eisai, Roche, and AstraZeneca outside the submitted work. Dr Perrone reported receiving personal fees from Bayer, Roche, Incyte, Ipsen, AstraZeneca, Sanofi, Astellas, Eli Lilly & Company, GSK, Boeringher Ingelheim, and Pfizer outside the submitted work. Dr Cinieri reported receiving personal fees from Lilly Oncology, Seagen, and AstraZeneca outside the submitted work. Dr Morano reported receiving honoraria from Servier and Eli Lilly & Company, research grants from Incyte, and nonfinancial travel support from Daiichi Sankyo outside the submitted work. Dr Pietrantonio reported receiving grants from BMS, Incyte, and AstraZeneca and personal fees from BMS, MSD, AstraZeneca, Amgen, Merck Serono, Eli Lilly & Company, Pierre Fabre, Servier, Bayer, and Organon outside the submitted work. No other disclosures were reported.

Additional Contributions: The Italian Association of Medical Oncology and Elma Academy staff helped in reviewing the data

References
1.
Safer  JD , Tangpricha  V .  Care of transgender persons.   N Engl J Med. 2019;381(25):2451-2460. doi:10.1056/NEJMcp1903650PubMedGoogle ScholarCrossref
2.
Turban  JL , Ehrensaft  D .  Research review: gender identity in youth: treatment paradigms and controversies.   J Child Psychol Psychiatry. 2018;59(12):1228-1243. doi:10.1111/jcpp.12833PubMedGoogle ScholarCrossref
3.
Zhang  Q , Goodman  M , Adams  N ,  et al.  Epidemiological considerations in transgender health: a systematic review with focus on higher quality data.   Int J Transgend Health. 2020;21(2):125-137. doi:10.1080/26895269.2020.1753136PubMedGoogle ScholarCrossref
4.
Wylie  K , Knudson  G , Khan  SI , Bonierbale  M , Watanyusakul  S , Baral  S .  Serving transgender people: clinical care considerations and service delivery models in transgender health.   Lancet. 2016;388(10042):401-411. doi:10.1016/S0140-6736(16)00682-6PubMedGoogle ScholarCrossref
5.
Reisner  SL , Poteat  T , Keatley  J ,  et al.  Global health burden and needs of transgender populations: a review.   Lancet. 2016;388(10042):412-436. doi:10.1016/S0140-6736(16)00684-XPubMedGoogle ScholarCrossref
6.
Winter  S , Diamond  M , Green  J ,  et al.  Transgender people: health at the margins of society.   Lancet. 2016;388(10042):390-400. doi:10.1016/S0140-6736(16)00683-8PubMedGoogle ScholarCrossref
7.
Wagner  AD , Oertelt-Prigione  S , Adjei  A ,  et al.  Gender medicine and oncology: report and consensus of an ESMO workshop.   Ann Oncol. 2019;30(12):1914-1924. doi:10.1093/annonc/mdz414PubMedGoogle ScholarCrossref
8.
James  SE , Herman  JL , Rankin  S , Keisling  M , Mottet  LA , Anafi  M .  The Report of the 2015 US Transgender Survey. National Center for Transgender Equality; 2016.
9.
European Union Agency for Fundamental Rights. Being trans in the EU—comparative analysis of the EU LGBT survey data. December 9, 2014. Accessed October 9, 2022. https://fra.europa.eu/en/publication/2014/being-trans-eu-comparative-analysis-eu-lgbt-survey-data
10.
Burns  ZT , Bitterman  DS , Liu  KX , Terezakis  SA , Neira  PM , Haas-Kogan  DA .  Towards a standard of care in oncology for transgender patients.   Lancet Oncol. 2019;20(3):331-333. doi:10.1016/S1470-2045(18)30942-2PubMedGoogle ScholarCrossref
11.
The Lancet Oncology.  Cancer risk in the transgender community.   Lancet Oncol. 2015;16(9):999. doi:10.1016/S1470-2045(15)00249-1PubMedGoogle ScholarCrossref
12.
Braun  H , Nash  R , Tangpricha  V , Brockman  J , Ward  K , Goodman  M .  Cancer in transgender people: evidence and methodological considerations.   Epidemiol Rev. 2017;39(1):93-107. doi:10.1093/epirev/mxw003PubMedGoogle ScholarCrossref
13.
de Blok  CJM , Dreijerink  KMA , den Heijer  M .  Cancer risk in transgender people.   Endocrinol Metab Clin North Am. 2019;48(2):441-452. doi:10.1016/j.ecl.2019.02.005PubMedGoogle ScholarCrossref
14.
Quinn  GP , Sanchez  JA , Sutton  SK ,  et al.  Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations.   CA Cancer J Clin. 2015;65(5):384-400. doi:10.3322/caac.21288PubMedGoogle ScholarCrossref
15.
Nash  R , Ward  KC , Jemal  A , Sandberg  DE , Tangpricha  V , Goodman  M .  Frequency and distribution of primary site among gender minority cancer patients: an analysis of US national surveillance data.   Cancer Epidemiol. 2018;54:1-6. doi:10.1016/j.canep.2018.02.008PubMedGoogle ScholarCrossref
16.
Hutchison  LM , Boscoe  FP , Feingold  BJ .  Cancers disproportionately affecting the New York State transgender population, 1979-2016.   Am J Public Health. 2018;108(9):1260-1262. doi:10.2105/AJPH.2018.304560PubMedGoogle ScholarCrossref
17.
Gooren  LJ , van Trotsenburg  MA , Giltay  EJ , van Diest  PJ .  Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.   J Sex Med. 2013;10(12):3129-3134. doi:10.1111/jsm.12319PubMedGoogle ScholarCrossref
18.
de Blok  CJM , Wiepjes  CM , Nota  NM ,  et al.  Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.   BMJ. 2019;365:l1652. doi:10.1136/bmj.l1652PubMedGoogle ScholarCrossref
19.
Brown  GR , Jones  KT .  Incidence of breast cancer in a cohort of 5135 transgender veterans.   Breast Cancer Res Treat. 2015;149(1):191-198. doi:10.1007/s10549-014-3213-2PubMedGoogle ScholarCrossref
20.
Silverberg  MJ , Nash  R , Becerra-Culqui  TA ,  et al.  Cohort study of cancer risk among insured transgender people.   Ann Epidemiol. 2017;27(8):499-501. doi:10.1016/j.annepidem.2017.07.007PubMedGoogle ScholarCrossref
21.
de Nie  I , de Blok  CJM , van der Sluis  TM ,  et al.  Prostate cancer incidence under androgen deprivation: nationwide cohort study in trans women receiving hormone treatment.   J Clin Endocrinol Metab. 2020;105(9):e3293-e3299. doi:10.1210/clinem/dgaa412PubMedGoogle ScholarCrossref
22.
Nota  NM , Wiepjes  CM , de Blok  CJM ,  et al.  The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment.   Brain. 2018;141(7):2047-2054. doi:10.1093/brain/awy108PubMedGoogle ScholarCrossref
23.
Wierckx  K , Mueller  S , Weyers  S ,  et al.  Long-term evaluation of cross-sex hormone treatment in transsexual persons.   J Sex Med. 2012;9(10):2641-2651. doi:10.1111/j.1743-6109.2012.02876.xPubMedGoogle ScholarCrossref
24.
Wierckx  K , Elaut  E , Declercq  E ,  et al.  Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.   Eur J Endocrinol. 2013;169(4):471-478. doi:10.1530/EJE-13-0493PubMedGoogle ScholarCrossref
25.
Boehmer  U , Gereige  J , Winter  M , Ozonoff  A , Scout  N .  Transgender individuals’ cancer survivorship: results of a cross-sectional study.   Cancer. 2020;126(12):2829-2836. doi:10.1002/cncr.32784PubMedGoogle ScholarCrossref
26.
Dhejne  C , Lichtenstein  P , Boman  M , Johansson  AL , Långström  N , Landén  M .  Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden.   PLoS One. 2011;6(2):e16885. doi:10.1371/journal.pone.0016885PubMedGoogle ScholarCrossref
27.
Jackson  SS , Han  X , Mao  Z ,  et al.  Cancer stage, treatment, and survival among transgender patients in the United States.   J Natl Cancer Inst. 2021;113(9):1221-1227. doi:10.1093/jnci/djab028PubMedGoogle ScholarCrossref
28.
Buchting  FO , Emory  KT , Scout  NFN ,  et al.  Transgender use of cigarettes, cigars, and e-cigarettes in a national study.   Am J Prev Med. 2017;53(1):e1-e7. doi:10.1016/j.amepre.2016.11.022PubMedGoogle ScholarCrossref
29.
Conron  KJ , Scott  G , Stowell  GS , Landers  SJ .  Transgender health in Massachusetts: results from a household probability sample of adults.   Am J Public Health. 2012;102(1):118-122. doi:10.2105/AJPH.2011.300315PubMedGoogle ScholarCrossref
30.
Downing  JM , Przedworski  JM .  Health of transgender adults in the US, 2014-2016.   Am J Prev Med. 2018;55(3):336-344. doi:10.1016/j.amepre.2018.04.045PubMedGoogle ScholarCrossref
31.
Kittaneh  AA , Patel  S , Sidhu  NK , Lechner  WV , Kenne  DR .  Tobacco use status as a function of transgender identity: the mediating role of psychological distress.   Tob Use Insights. 2021;14:X211004267. doi:10.1177/1179173X211004267PubMedGoogle ScholarCrossref
32.
De Pedro  KT , Gilreath  TD , Jackson  C , Esqueda  MC .  Substance use among transgender students in California public middle and high schools.   J Sch Health. 2017;87(5):303-309. doi:10.1111/josh.12499PubMedGoogle ScholarCrossref
33.
Day  JK , Fish  JN , Perez-Brumer  A , Hatzenbuehler  ML , Russell  ST .  Transgender youth substance use disparities: results from a population-based sample.   J Adolesc Health. 2017;61(6):729-735. doi:10.1016/j.jadohealth.2017.06.024PubMedGoogle ScholarCrossref
34.
Wheldon  CW , Wiseman  KP .  Tobacco use among transgender and gender non-conforming adults in the United States.   Tob Use Insights. 2019;12:X19849419. doi:10.1177/1179173X19849419PubMedGoogle ScholarCrossref
35.
Hoffman  L , Delahanty  J , Johnson  SE , Zhao  X .  Sexual and gender minority cigarette smoking disparities: an analysis of 2016 Behavioral Risk Factor Surveillance System data.   Prev Med. 2018;113:109-115. doi:10.1016/j.ypmed.2018.05.014PubMedGoogle ScholarCrossref
36.
Meyer  IH , Brown  TN , Herman  JL , Reisner  SL , Bockting  WO .  Demographic characteristics and health status of transgender adults in select US regions: behavioral risk factor surveillance system, 2014.   Am J Public Health. 2017;107(4):582-589. doi:10.2105/AJPH.2016.303648PubMedGoogle ScholarCrossref
37.
Williams  EC , Frost  MC , Rubinsky  AD ,  et al.  Patterns of alcohol use among transgender patients receiving care at the Veterans Health Administration: overall and relative to nontransgender patients.   J Stud Alcohol Drugs. 2021;82(1):132-141. doi:10.15288/jsad.2021.82.132PubMedGoogle ScholarCrossref
38.
Blosnich  JR , Lehavot  K , Glass  JE , Williams  EC .  Differences in alcohol use and alcohol-related health care among transgender and nontransgender adults: findings from the 2014 Behavioral Risk Factor Surveillance System.   J Stud Alcohol Drugs. 2017;78(6):861-866. doi:10.15288/jsad.2017.78.861PubMedGoogle ScholarCrossref
39.
Becasen  JS , Denard  CL , Mullins  MM , Higa  DH , Sipe  TA .  Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006-2017.   Am J Public Health. 2019;109(1):e1-e8. doi:10.2105/AJPH.2018.304727PubMedGoogle ScholarCrossref
40.
Baral  SD , Poteat  T , Strömdahl  S , Wirtz  AL , Guadamuz  TE , Beyrer  C .  Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.   Lancet Infect Dis. 2013;13(3):214-222. doi:10.1016/S1473-3099(12)70315-8PubMedGoogle ScholarCrossref
41.
Dunne  EF , Park  IU .  HPV and HPV-associated diseases.   Infect Dis Clin North Am. 2013;27(4):765-778. doi:10.1016/j.idc.2013.09.001PubMedGoogle ScholarCrossref
42.
Viens  LJ , Henley  SJ , Watson  M ,  et al.  Human papillomavirus-associated cancers—United States, 2008-2012.   MMWR Morb Mortal Wkly Rep. 2016;65(26):661-666. doi:10.15585/mmwr.mm6526a1PubMedGoogle ScholarCrossref
43.
Stier  EA , Sebring  MC , Mendez  AE , Ba  FS , Trimble  DD , Chiao  EY .  Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review.   Am J Obstet Gynecol. 2015;213(3):278-309. doi:10.1016/j.ajog.2015.03.034PubMedGoogle ScholarCrossref
44.
Fein  LA , Rosa Cunha  I , Slomovitz  B , Potter  J .  Risk factors for anal dysplasia in transgender women: a retrospective chart review.   J Low Genit Tract Dis. 2018;22(4):336-339. doi:10.1097/LGT.0000000000000396PubMedGoogle ScholarCrossref
45.
Fein  LA , Cunha  IR , Wong  A , Schlumbrecht  MP , Duthely  LM , Potter  JE .  Low perceived anal cancer risk and screening utilization among high-risk transgender men and women living in an HIV / STI epicenter.   AIDS Behav. 2021;25(7):2210-2218. doi:10.1007/s10461-020-03149-wPubMedGoogle ScholarCrossref
46.
Brown  B , Poteat  T , Marg  L , Galea  JT .  Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: neglected populations at high risk.   LGBT Health. 2017;4(5):315-319. doi:10.1089/lgbt.2016.0142PubMedGoogle ScholarCrossref
47.
Jalil  EM , Wilson  EC , Monteiro  L ,  et al.  High prevalence of anal high-risk HPV infection among transwomen: estimates from a Brazilian RDS study.   J Int AIDS Soc. 2021;24(3):e25691. doi:10.1002/jia2.25691PubMedGoogle ScholarCrossref
48.
Brown  B , Galea  JT , Byraiah  G ,  et al.  Anogenital human papillomavirus infection and HIV infection outcomes among Peruvian transgender women: results from a cohort study.   Transgend Health. 2016;1(1):94-98. doi:10.1089/trgh.2016.0001PubMedGoogle ScholarCrossref
49.
Loverro  G , Di Naro  E , Caringella  AM , De Robertis  AL , Loconsole  D , Chironna  M .  Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy.   Sex Transm Infect. 2016;92(1):67-69. doi:10.1136/sextrans-2014-051987PubMedGoogle ScholarCrossref
50.
van der Sluis  WB , Buncamper  ME , Bouman  MB ,  et al.  Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands.   Sex Transm Dis. 2016;43(8):503-505. doi:10.1097/OLQ.0000000000000476PubMedGoogle ScholarCrossref
51.
Reisner  SL , Deutsch  MB , Peitzmeier  SM ,  et al.  Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients.   PLoS One. 2018;13(3):e0190172. doi:10.1371/journal.pone.0190172PubMedGoogle ScholarCrossref
52.
Hariri  S , Unger  ER , Sternberg  M ,  et al.  Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006.   J Infect Dis. 2011;204(4):566-573. doi:10.1093/infdis/jir341PubMedGoogle ScholarCrossref
53.
Weyers  S , Garland  SM , Cruickshank  M , Kyrgiou  M , Arbyn  M .  Cervical cancer prevention in transgender men: a review.   BJOG. 2021;128(5):822-826. doi:10.1111/1471-0528.16503PubMedGoogle ScholarCrossref
54.
Peitzmeier  SM , Khullar  K , Reisner  SL , Potter  J .  Pap test use is lower among female-to-male patients than non-transgender women.   Am J Prev Med. 2014;47(6):808-812. doi:10.1016/j.amepre.2014.07.031PubMedGoogle ScholarCrossref
55.
Peitzmeier  SM , Reisner  SL , Harigopal  P , Potter  J .  Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening.   J Gen Intern Med. 2014;29(5):778-784. doi:10.1007/s11606-013-2753-1PubMedGoogle ScholarCrossref
56.
Tabaac  AR , Sutter  ME , Wall  CSJ , Baker  KE .  Gender identity disparities in cancer screening behaviors.   Am J Prev Med. 2018;54(3):385-393. doi:10.1016/j.amepre.2017.11.009PubMedGoogle ScholarCrossref
57.
Kiran  T , Davie  S , Singh  D ,  et al.  Cancer screening rates among transgender adults: cross-sectional analysis of primary care data.   Can Fam Physician. 2019;65(1):e30-e37.PubMedGoogle Scholar
58.
Porsch  LM , Dayananda  I , Dean  G .  An exploratory study of transgender New Yorkers’ use of sexual health services and interest in receiving services at Planned Parenthood of New York City.   Transgend Health. 2016;1(1):231-237. doi:10.1089/trgh.2016.0032PubMedGoogle ScholarCrossref
59.
Agénor  M , White Hughto  JM , Peitzmeier  SM ,  et al.  Gender identity disparities in Pap test use in a sample of binary and non-binary transmasculine adults.   J Gen Intern Med. 2018;33(7):1015-1017. doi:10.1007/s11606-018-4400-3PubMedGoogle ScholarCrossref
60.
Goldstein  DA , Sarkodie  E , Hardy  WD .  Transgender and nontrans patients do not receive statistically different quality primary care at Whitman-Walker Health, 2008-2016.   Transgend Health. 2019;4(1):200-208. doi:10.1089/trgh.2019.0022PubMedGoogle ScholarCrossref
61.
Bazzi  AR , Whorms  DS , King  DS , Potter  J .  Adherence to mammography screening guidelines among transgender persons and sexual minority women.   Am J Public Health. 2015;105(11):2356-2358. doi:10.2105/AJPH.2015.302851PubMedGoogle ScholarCrossref
62.
Narayan  A , Lebron-Zapata  L , Morris  E .  Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey.   Breast Cancer Res Treat. 2017;166(3):875-879. doi:10.1007/s10549-017-4461-8PubMedGoogle ScholarCrossref
63.
Ma  SJ , Oladeru  OT , Wang  K ,  et al.  Prostate cancer screening patterns among sexual and gender minority individuals.   Eur Urol. 2021;79(5):588-592. doi:10.1016/j.eururo.2020.11.009PubMedGoogle ScholarCrossref
64.
Kerr  L , Fisher  CM , Jones  T .  “I’m not from another planet”: the alienating cancer care experiences of trans and gender-diverse people.   Cancer Nurs. 2021;44(6):E438-E446. doi:10.1097/NCC.0000000000000857PubMedGoogle ScholarCrossref
65.
Alpert  AB , Gampa  V , Lytle  MC ,  et al.  I’m not putting on that floral gown: enforcement and resistance of gender expectations for transgender people with cancer.   Patient Educ Couns. 2021;104(10):2552-2558. doi:10.1016/j.pec.2021.03.007PubMedGoogle ScholarCrossref
66.
Moloney  C , Allen  M , Power  DG ,  et al.  Assessing the quality of care delivered to transgender and gender diverse patients with cancer in Ireland: a case series.   Oncologist. 2021;26(4):e603-e607. doi:10.1002/onco.13618PubMedGoogle ScholarCrossref
67.
Burns  ZT , Bitterman  DS , Perni  S ,  et al.  Clinical characteristics, experiences, and outcomes of transgender patients with cancer.   JAMA Oncol. 2021;7(1):e205671. doi:10.1001/jamaoncol.2020.5671PubMedGoogle ScholarCrossref
68.
Kamen  CS , Alpert  A , Margolies  L ,  et al.  “Treat us with dignity”: a qualitative study of the experiences and recommendations of lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer.   Support Care Cancer. 2019;27(7):2525-2532. doi:10.1007/s00520-018-4535-0PubMedGoogle ScholarCrossref
69.
Neumann  MS , Finlayson  TJ , Pitts  NL , Keatley  J .  Comprehensive HIV prevention for transgender persons.   Am J Public Health. 2017;107(2):207-212. doi:10.2105/AJPH.2016.303509PubMedGoogle ScholarCrossref
70.
Saslow  D , Andrews  KS , Manassaram-Baptiste  D , Smith  RA , Fontham  ETH ; American Cancer Society Guideline Development Group.  Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation.   CA Cancer J Clin. 2020;70(4):274-280. doi:10.3322/caac.21616PubMedGoogle ScholarCrossref
71.
Pratt-Chapman  ML , Ward  AR .  Provider recommendations are associated with cancer screening of transgender and gender-nonconforming people: a cross-sectional urban survey.   Transgend Health. 2020;5(2):80-85. doi:10.1089/trgh.2019.0083PubMedGoogle ScholarCrossref
72.
Griggs  J , Maingi  S , Blinder  V ,  et al.  American Society of Clinical Oncology position statement: strategies for reducing cancer health disparities among sexual and gender minority populations.   J Clin Oncol. 2017;35(19):2203-2208. doi:10.1200/JCO.2016.72.0441PubMedGoogle ScholarCrossref
73.
Quinn  GP , Alpert  AB , Sutter  M , Schabath  MB .  What oncologists should know about treating sexual and gender minority patients with cancer.   JCO Oncol Pract. 2020;16(6):309-316. doi:10.1200/OP.20.00036Google ScholarCrossref
74.
Alpert  A , Cicero  E .  Removing barriers to health care for transgender people with and without cancer.   Ethics Med Public Health. 2020;13:100468. doi:10.1016/j.jemep.2020.100468Google ScholarCrossref
75.
Seay  J , Hicks  A , Markham  MJ ,  et al.  Web-based LGBT cultural competency training intervention for oncologists: pilot study results.   Cancer. 2020;126(1):112-120. doi:10.1002/cncr.32491PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue